Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that has been associated with recurrent mutations in a number of regulators of immature T cell differentiation, proliferation and survival including the genes encoding NOTCH1, LMO2, HOXA11, LYL1, and TAL1 [1, 2] . Notch1 is a receptor that undergoes proteolytic cleavage to release its intracellular domain (ICN) as a transcription regulator, which serves a key role in normal thymocyte differentiation and is a frequent target of gain-offunction mutations in T-ALL. Notch1 was identified at a recurrent (7;9) (q34;34.3) translocation in T-ALL that fuses the 3 portion of NOTCH1 to the TCR-␤ locus, leading to expression of constitutively active forms of the Notch1 receptor (TAN1) [3] . This translocation is present in <1% of human T-ALL but several studies have provided evidence that Notch signalling in T cell leukemias and lymphomas is often elevated even in the absence of genomic rearrangements [4, 5] . Somatic mutations that alter the NOTCH1 protein-coding sequence have been found in more than 50% of human T-ALL with diverse molecular subtypes [6] . These were found largely in the extracellular heterodimerization (HD) domain, and truncating or missense mutations in the C-terminal PEST domain that increase stability of ICN [6] [7] [8] [9] [10] . The extent to which these individual NOTCH1 mutations in T-ALL confer a growth advantage or malignant transformation is unclear. T-ALL have been described with multiple NOTCH1 mutations in cis altering the HD and C-terminal domains, and these have been shown to exaggerate NOTCH1 activity in tissue culture in an additive manner and to function cooperatively for leukemogenesis in vivo [7, [9] [10] [11] [12] . Some T-ALL NOTCH1 mutations are sufficient for promoting leukemogenesis while others are only sufficient for leukemogenesis in conjunction with other mutations, raising the question of how many cooperating events precede the first outgrowth of a leukemic T cell clone [13] [14] [15] [16] .
Notch1 heterodimers comprising noncovalently associated extracellular domain (NEC) and transmembrane domains (NTM) are produced by the cleavage of pro-Notch1 by a furin-like protease during transit to the cell surface [17] . Activation of Notch receptors occur upon binding of Notch Delta-Serrate-Lag2 (DSL) ligands to the EGF repeat region of the NEC leading to cleavage at S2 in the extracellular portion of NTM, creating a short-lived membrane-bound NTM which is subject to mono-ubiquitination by FBXW7 to promote endocytosis and cleavage by ␥-secretase at the S3 site which releases the intracellular domain of NTM (ICN) [17] . The ICN then translocates into the nucleus and associates with the transcription factor CSL or RBP-J and Mastermind-like 1-3 [17] . This complex activates transcription of Notch target genes including Myc, PTEN/PI3K, NFkB, Hes1, PreT˛ [18] . Not only mutations in NOTCH1 itself can lead to leukemogenesis, cooperating mutations in Notch target genes [19] and regulators (e.g. FBXW7 [20, 21] and Ikaros [22] [23] [24] ) have been identified.
Mice with germline mutations that inactivate the transcriptional regulator Ikaros (gene symbol Ikzf1) develop T-ALL exclusively [23, 25] and the resulting malignancies often have activating NOTCH1 mutations [6, 23, 24] . Ikzf1 somatic mutations are also frequently found in combination with NOTCH1 mutations in mouse retrovirus-promoted T-ALL [18] and in human B-ALL and T-ALL [26, 27] . Short, dominant negative forms of Ikaros generated by alternative splicing have also been found in human T-ALL [28, 29] although this has not been found in other T-ALL series [30] . Ikaros mRNA can undergo alternative splicing to yield a range of isoforms some of which lack DNA binding domains (e.g. Ikzf1 4-9 isoforms) and so are unable to function as transcriptional regulators but dimerize to act as dominant negative inhibitors of full length Ikaros [31] . Ikaros mutations select for the expression of these short dominant-interfering splice forms.
The relationship between Ikaros and Notch1 in thymocyte differentiation and leukemogenesis is incompletely understood. Full length Ikaros and RBP-J recognize the same DNA binding sequence where Ikaros can inhibit RBP-J binding and stimulation of transcription [22] , but it is not known if Ikaros simply acts as a competitive repressor of Notch-target genes. Animal models of T-ALL provide a unique opportunity to study the cooperating events needed for the initial outgrowth of leukemic T cells, but so far studies have focussed on the malignant phase when overt leukemia and lymphadenopathy have ensued. Here, by analysing pre-leukemic stages in the evolution of T-ALL in mice with an inactivating Ikaros point mutation, we present evidence that Ikaros negatively regulates the Notch1 pathway at the DP thymocyte stage. The first detectable clonal outgrowth occurs selectively within the thymus around the DP stage of development, closely correlated with somatic loss of the remaining wild-type Ikaros allele, a 10-1000 fold increase in mRNA from Notch-response genes, and accumulation of somatic Notch1 mutations. These results indicate that multiple mutations are needed and act cooperatively to activate the Notch1 pathway before pre-leukemic thymocyte outgrowth becomes detectable.
Methods

Animals
Ikzf1 Plstc/+ mice were bred with C57BL/6 J background (Jackson Laboratory) and maintained in the Australian Phenomics Facility and all procedures were approved by the Australian National University Animal Experimentation Ethics Committee.
Flow cytometry
Lymphoid tissues were prepared as single cell suspensions in ice-cold PBS/10% FCS and stained with fluorochrome labelled monoclonal antibodies prior to FACS analysis on a FACS Calibur flow cytometer and the data analysed with FlowJo (Tree Star) software.
Real time RT-PCR
DP thymocytes were sorted on FACSAria/Vantage (Becton Dickinson) and were ≥99% pure and total RNA was isolated using Trizol reagent (1 ml per 5-10 × 10 6 cells) and reverse transcribed to cDNA using SUPERSCRIPT First Strand cDNA Synthesis kit (Invitrogen). Samples were stored at −20 • C prior to use. Real-time RT-PCR was performed using the TaqMan ® Gene Expression Assays (Applied Biosystems) on 384-well plate platform on the ABI PRISM ® 7900HT (Applied Biosystems). Relative quantification of mRNA level was performed using the comparative cycle threshold (CT) following the manufacturer's instruction.
Analysis of Ikaros LOH
Genomic DNA samples were prepared from sorted cells from Ikzf1 +/+ and Ikzf1 Plstc/+ mice and DNA was analysed for the loss of the wild type Ikaros allele by MS-PCR [32] and Amplifluor ® PCR. End-point fluorescence intensity for the PCR products were analysed by FLUOstar OPTIMA (BMG Labtech). Positive controls included DNA from Ikzf1 +/+ and Ikzf1 Plstc/Plstc embryos that was used to generate a standard curve. Using the standard curve it was possible to calculate the percentage of the wild type allele within the Ikzf1 Plstc/+ samples.
Exonic sequencing for Notch 1 mutations
Mutation detection in exons 26, 27 and 34 of Notch1 was performed via PCR using primers specific for exons 26 PCR cycles included 97 • C for 3 min, 94 • C for 30 s, annealing at 59 • C for 60 s, extension at 72 • C for 90 s. PCR products (5 l) were visualised on a 1.5% (w/v) agarose gel with 5× DNA loading dye. The amplification was repeated in triplicate. The PCR products were purified using PureLink TM PCR Purification Kit (Invitrogen) according to the manufacturer's instructions. DNA was eluted in 50 l of water.
Sequencing
PCR products were gel purified using PureLink TM Quick Gel Extraction Kit (Invitrogen) according to the manufacturer's instructions. DNA was dissolved into 50 l of water and the concentration determined by NanoDrop (ND1000). Addition of 3 adenine to the amplified product was performed prior to cloning the product into TOPO TA Cloning ® System (Invitrogen) according to the manufacturer's instructions. Plasmid DNA was transformed into One Shot ® Chemically competent E. coli cells (Invitrogen) with a 30 s heat shock at 42 • C followed by incubation at 37 • C for 1 h. 10-50 l of each transformation was spread on a selective plate containing 100 g/ml ampicillin (Invitrogen) and X-gal (Invitrogen) and incubated overnight at 37 • C. Approximately 12 white or light blue colonies per plate were picked and cultured on 96-well growth block (Invitrogen) containing LB media with 100 g/ml ampicillin. Purified plasmids of twelve clones per tumour sample were sequenced in the Biomedical Research Facility of John Curtin School of Medical Research.
Luciferase assays
Hes1-Luciferase (Hes-1-Luc) [33] and Hey1-Luc reporter gene [34] used contain Hes1 promoter and Hey1 promoter regions, respectively. Each promoter region contains two RBP-Jk binding sites. NIH3T3 cells were grown in DMEM containing 10% FCS. Transfections were performed in C2C12 cells using LipofectAMINE and Plus reagent (Invitrogen) according to the manufacturer's instructions. Luciferase assay transfections in 12-well trays contained 14 ng of CMV-Renilla plasmid, 350 ng of Hes1-Luc or Hey1-Luc and 350 ng of each expression plasmid (pCMX-ICN, pCMX-Ikzf1, pCMX-Ikzf1 Plstc ) or pCAT-CMX control plasmid. Firefly and Renilla luciferase activities were assayed using the Dual-luciferase reporter system (Promega) and measured on a FLUOstar Optima Luminometer (BMG). Firefly luciferase counts were normalised against Renilla luciferase counts to account for differences in transfection efficiency.
Results
Expanded populations of CD8 + CD4 low TCRˇh i thymocytes with LOH mutations
To identify the early steps leading to T-ALL, we systematically analysed the thymi of a large cohort of Ikzf1 Plstc/+ mice during the pre-leukemic phase between 4 and 12 weeks of age when ≥90% of animals remain disease free ( Fig. 1A ). Up to 6 weeks of age there was no difference in CD4 or CD8 differentiation in the thymus of wild type and Ikzf1 Plstc/+ mice (data not shown) but by 8-12 weeks of age most Ikzf1 Plstc/+ mice exhibited a larger shoulder of CD8 + CD4 low cells below the normal DP thymocyte population despite normal or only slightly elevated numbers of thymocytes ( Fig. 1B) . These abnormal CD8 + CD4 low cells in the thymus were typically TCR␤ hi CD5 hi , comparable to post-positive selection CD8 SP cells in normal thymi, except that they were CD69 negative whereas most normal CD8 SP cells are CD69 + (Supplemental Fig. 1 ). The DP population itself also exhibited increased expression of TCR␤, CD3 and CD5 in these individuals (Supplemental Fig. 1 ). Staining for spe-cific V␤ regions showed monoclonal or oligoclonal expansion of TCR-V␤ cells (e.g. TCR-V␤5 hi or TCR-V␤8.3 hi cells) in the thymus of a subset of animals aged 10-12 weeks, but these expanded T cell clones were not detected in the peripheral lymphoid tissues at this age (Supplemental Fig. 2 ). In the majority of 8-to 12-week-old mice with these early stage abnormalities, the number and phenotype of peripheral lymphocytes was normal, and hence these animals are referred to as "pre-leukemic". However a minority of mice at 12 weeks of age had low frequencies of abnormal DP cells in the thymus and spleen (e.g. mouse G17.2 in Fig. 1B) . Flow cytometric analysis of the peripheral DP cells in the spleen revealed that they shared an identical cellular phenotype that were typically TCR␤ hi CD5 hi . The similar phenotype between thymocytes and splenocytes suggests that the peripheral DP phenotype cells were thymic derived and did not arise spontaneously in the periphery (Supplemental Figs. 3 and 4) . The indication above that abnormal leukemic clones evolve initially within the thymus was investigated further by testing thymocytes for somatic Ikzf1 loss of heterozygosity (LOH). DP thymocytes were sorted from individual mice in a 6-to 12-week-old cohort, genomic DNA prepared, and a quantitative fluorescent SNP assay used to measure the amount of Ikzf1 +/+ and Ikzf1 Plstc/+ DNA in each sample ( Fig. 2A ). This revealed that DP thymocytes in the majority of the Ikzf1 Plstc/+ mice retained the wild-type Ikzf1 allele in heterozygous state up to 6 weeks of age but this allele accounted for less than 25% of Ikzf1 DNA or became undetectable in a progressively increasing proportion of 8-to 12-week-old mice (Fig. 2B ). The extent of Ikzf1 LOH in DP cells of individual mice correlated with the extent of flow cytometric abnormalities (Fig. 2C ). Somatic loss of wild-type Ikaros in DP thymocytes occurred in animals that did not have thymic lymphoma nor peripheral leukemia. For example, the wild type Ikaros allele was less than 10% or undetectable in DP cells from G17.23 and G16.62, respectively (Fig. 2B ), yet total thymocyte numbers in these individuals were only twice normal ( Fig. 1B ) and the expanded thymic clone of TCR-V␤8.3 + or TCR-V␤5 + T cells was undetectable in peripheral tissues (Supplemental Fig. 2 ).
Somatic loss of LOH correlates with a large increase in Notch target gene expression in DP thymocytes
In parallel with the flow cytometric and LOH analyses of the cohort of Ikzf1 Plstc/+ mice above, mRNA was prepared from the same samples of sorted DP cells and used to measure expression of Notch target genes and other developmental genes by real-time PCR. We focussed first on Hes1 which was of particular functional relevance because its product is known to suppress CD4 expression [35] and hence might explain the CD8 + CD4 low phenotype of the earliest detectable abnormal thymocytes. Compared to control DP cells sorted in parallel from wild-type mice, Hes1 mRNA was modestly elevated in 6-to 8-week-old mice with no evidence of an abnormal CD4-CD8 profile, but became dramatically increased to 100-1000 times the normal DP cell levels in DP cells from 10-to 12-week-old Ikzf1 Plstc/+ mice ( Fig. 3A and Supplemental Fig. 5 ). Increased Hes1 mRNA was inversely correlated with loss of wild-type Ikzf1 in DP thymocytes (Fig. 3A , r = −0.77), and with increased percentage of CD8 + CD4 low thymocytes measured flow cytometrically (Fig. 3B , r = 0.82). Thus, while the heterozygous Ikaros point mutation did not result in any appreciable increase in expression of the Notch1 target gene Hes1 in DP thymocytes that retained 50% wild-type Ikzf1 DNA, the proportion of thymocytes that had lost the wildtype allele was closely correlated with dramatically exaggerated Hes1 expression.
Ikaros LOH in DP thymocytes was closely correlated (r = −0.79) with a 10-100 fold increase in Dtx1 expression ( Fig. 3C) . Expression of pre-Ta, which is both developmentally regulated and Notch1 regulated [36] , was increased in most samples with LOH but less well correlated (Fig. 3C , r = −0.58). There was little correlation between Ikzf1 LOH and mRNA expression of Rag1 gene, which is not known to be a direct Notch1 target (Fig. 3C, r = −0.24) .
The evidence above that the remaining wild type Ikaros allele in Ikzf1 Plstc/+ DP cells served as a critical negative regulator for 
% wild
RaƟo CD8 / DP ce lls Notch1-induced gene expression was corroborated in cell lines bearing luciferase reporters controlled by promoter elements from two different Notch target genes, Hes1 and Hey1. Co-transfection of DNA encoding the wild-type Ikaros full-length isoform (Ik1) inhibited transcriptional induction by DNA encoding the intracellular domain of Notch1 (ICN). By contrast, co-transfection of DNA encoding Ik1 bearing the H191R mutation was unable to repress activation of the Hes1 or Hey1 reporter constructs (Fig. 4) . These results are consistent with other evidence that Ikaros negatively regulates Notch1 target gene expression [22, 23, 35, [37] [38] [39] . Since the H191R point mutation disrupts DNA binding but leaves expression of otherwise normal full-length Ikaros isoforms in DP cells, these results collectively establish that the inhibitory effect of Ikaros on transcription of Notch1 targets in DP cells requires the DNA recognition domain and cannot be supplied through other parts of the full-length Ikaros protein. Hes1-reporter Hey1-reporter 
Notch1 missense and PEST truncation mutations accompany Ikaros LOH at the earliest detectable stages of abnormal thymopoiesis
In parallel with analysing Ikaros LOH and Notch1-target gene expression in the cohort of pre-leukemic Ikzf1 Plstc/+ mice, we PCR amplified, cloned and sequenced Notch1 exons 26 and 27 encoding the HD domain and exon 34 encoding the C-terminal PEST domain from genomic DNA of the sorted DP cells ( Table 1 and Supplemental Figs. 6 and 7) . In DP cells from 12 Ikzf1 Plstc/+ mice aged between 4 and 8 weeks of age with no thymic flow cytometric abnormalities, 3 independent insertion/deletions were detected in exon 34 that truncate ICN (2 in 4-week-old mouse G17.59; 1 in 8-week-old G17.1). These two animals also had little or no increase in Hes1 mRNA in DP cells and retained a wild-type Ikzf1 allele in the majority of cells (Fig. 3A) . ICN truncating mutations were found at a higher rate (9 mutations in 7 of 11 mice tested) in DP cells from mice with flow cytometrically abnormal thymocytes, despite many lacking detectable leukemia (e.g. G17.23). Of the flow cytometrically abnormal samples with ICN-truncating mutations, all that were tested also had complete or near-complete Ikzf1 LOH and 50-1000 fold increased Hes1 mRNA (Fig. 3A, , including several such as L1668P (L1679P in human NOTCH1) that are repeatedly found in human T-ALL and are well established to destabilize the HD domain negative regulatory region [10] . While a comparable rate of nucleotide substitutions was found in thymic samples with normal or abnormal flow cytometry, the replacement-to-silent ratio was consistent with selection for replacements in DP cells from thymi with abnormal flow cytometric profiles (R/S = 6) whereas there was no evidence for selection in samples without flow cytometric abnormalities (R/S = 1.4). Because the different exons were amplified separately, we cannot determine if the HD missense mutations were combined in cis with ICN truncating mutations as has been observed in human T-ALL. Thus, while potentially activating Notch1 mutations precede the first flow cytometrically detectable thymocyte abnormalities in preleukemic animals, the transition to detectably abnormal thymopoiesis is accompanied by strong selection for activating Notch1 Contributions: CCG and GFH are equal senior authors; YS performed the majority of studies; GC performed studies shown in Fig. 4 ; PP performed studies in Fig. 1 and also in unpublished studies related to the manuscript; SLD helped design studies shown in Fig. 4 and contributed to writing and CCG and GFH helped to plan and direct experiments and writing of the manuscript.
